Letter to the editor on cross-protection of RotaTeqTM

Ma et al estimated the effectiveness of RotaTeqTM (pentavalent rotavirus vaccine, RV5), containing human bovine reassortants G1, G2, G3, G4 and P[8], against rotavirus gastroenteritis at 97% (95% CI, 83%-100%) in a cohort of children (14 weeks to 2 years of age) predominantly infected (79%) with G8P[8], in Shanghai, China (1). RV5 has been shown to be efficacious and effective across geographic settings, time-periods, and strains, but protection of RV5 against a G8 strain had been demonstrated previously only in Africa (2-6).
Source: The Journal of Pediatrics - Category: Pediatrics Authors: Tags: Letters to the Editor Source Type: research